⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12645490 | 1.00 | — | — | |
| SCHEMBL13615467 | 0.74 | MAPT (0.45) | — | |
| SCHEMBL13219039 | 0.74 | — | — | |
| SCHEMBL9678950 | 0.74 | — | — | |
| SCHEMBL23133030 | 0.72 | — | — | |
| SCHEMBL25406639 | 0.72 | — | — | |
| SCHEMBL10508166 | 0.72 | — | — | |
| SCHEMBL25407367 | 0.72 | — | — | |
| SCHEMBL10508164 | 0.72 | — | — | |
| SCHEMBL11307774 | 0.72 | GAA (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-02-07 | — | — | US | disclosed |
| US-9844572-B2 | Promotion of neuronal integration in neural stem cell grafts | LIFE & BRAIN GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2411034-B1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017106552-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AND COMBINATION THERAPY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2010108665-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | LIFE & BRAIN GMBH (DE) | 2010-09-30 | — | — | WO | disclosed |
| US-7749990-B2 | [3-(2,6-Dimethylbenzyloxy)-phenyl]-oxoacetic acid, useful for the treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | disclosed |
| US-20090005451-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-01-01 | — | — | US | disclosed |
| US-7442796-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070173544-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-07-26 | — | — | US | disclosed |
| US-20070173544-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-07-26 | — | — | US | disclosed |